Haptoglobin and Iron in Parkinson's Disease (HPPD)
Haptoglobin Phenotype and Smoking: Effects on Iron Levels in Parkinson's Disease
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
A total of 342 participants, 100 PD patients and 242 age- and gender matched controls, were included in the study. All study participants were seen for one study visit in the morning at one of two Bastyr University Clinics in the Seattle area. Study participants were fasting at the time of the visit. During the study visit, participants donated a blood sample for the blood tests and complete an epidemiology questionnaire.
A subset of 51 of the study participant who were seen for the visit at Bastyr University, underwent brain scan and Magnetic Resonance Imaging (MRI), at the University of Washington Department of Radiology. The MRI part of the study aims at estimating brain iron levels.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
San Diego, California, Förenta staterna, 92093
- University of California
-
-
Washington
-
Kenmore, Washington, Förenta staterna, 98028
- Bastyr University Research Institute
-
Seattle, Washington, Förenta staterna, 98195
- University of Washington
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Parkinson's disease patients will be included in the study if they received a diagnosis of Parkinson's disease that meets the United Kingdom Brain Bank (UKBB) clinical criteria of Parkinson's disease diagnosis.
Control participants will be included in the study if free of neurodegenerative diseases.
A subset of the study participants (60 total) receive Magnetic Resonance Imaging to estimate brain iron
Beskrivning
Inclusion Criteria for the Controls, for the blood draw and epidemiology visit:
- Volunteers should be of age between 52 and 82 years of age, males of females.
Exclusion Criteria for the Controls:
- presence of a neurodegenerative disease,
- presence of active cancer under treatment,
- HIV sero-positivity, Hepatitis B, C, of A sero-positivity
- rheumatoid arthritis
- recent blood donation (less than three months before the visit).
- fever at the time of the visit
Inclusion Criteria for the Parkinson's disease patients:
Diagnosis of Parkinson's disease (UKBB clinical criteria).
Exclusion criteria for the Parkinson's disease patients, for the blood draw and epidemiology visit:
- Presence of other neurodegenerative diseases, apart for Parkinson's disease
- two or more family members with Parkinson's disease
- presence of active cancer under treatment
- HIV sero-positivity, Hepatitis B, C, of A sero-positivity
- rheumatoid arthritis
- recent blood donation (less than three months before the visit).
- fever at the time of the visit
Exclusion criteria for the Magnetic Resonance Imaging:
- presence in the body of a ferro-magnetic metallic foreign object such as, but not limited to:
- a cardiac pacemaker
- aneurism clip
- neuro-stimulator
- surgical clip
- artificial limb or joint
- orthopedic items, such as screws, nails, pins, rods,
- any metallic foreign body from a previous injury, bullets, shrapnels, metal slivers.
- exclusion criteria for MRI is also the presence of claustrophobia
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
PD
100 PD patients were patients diagnosed with Parkinson's disease
|
|
Controls
242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Iron metabolism differences between PD patients and controls
Tidsram: Up to 7 years
|
Iron metabolism will be measured by testing for serum iron and iron-binding proteins, and by estimating brain iron by MRI.
Serum iron parameters that will be measured include total serum iron, iron-binding proteins such as transferrin and ferritin, and tests related to iron metabolism: transferrin % saturation, unsaturated iron binding capacity, soluble transferrin receptor, complete blood count, hemoglobin, uric acid, haptoglobin, haptoglobin phenotype.
Differences in serum iron parameters, and brain iron levels, between PD patients and controls will be calculated.
|
Up to 7 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Environmental factors affecting PD risk and gene-environment interactions
Tidsram: recruitment until January 2016
|
Questionnaire data will be analyzed to identify risk factors for PD by comparing lifestyle and dietary patterns from questionnaire between PD cases and controls.
Interaction between haptoglobin phenotype and tobacco smoking on PD risk will be calculated, as well as interaction between haptoglobin phenotype and environmental factors such as tobacco smoking and diet on serum iron and brain iron levels.
|
recruitment until January 2016
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Paola Costa-Mallen, PhD, Bastyr University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 12A-1330
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .